Tofacitinib for the treatment of lichen planopilaris: A case series
September 2018
in “Dermatologic therapy”
TLDR Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
In this case series, 10 patients with recalcitrant lichen planopilaris (LPP) were treated with oral tofacitinib, a Janus kinase (JAK) inhibitor, at doses of 5 mg twice or three times daily for 2–19 months. The treatment was administered either as monotherapy or in combination with other therapies. Eight patients showed clinical improvement, with significant reductions in the LPP Activity Index (LPPAI) from an average of 6.22 before treatment to 3.08 after treatment (p = .0014), indicating a reduction in LPPAI ranging from 30 to 94%. One patient experienced a 10-pound weight gain, but no other adverse effects were reported. The study concluded that oral tofacitinib could lead to measurable improvement in recalcitrant LPP.
View this study on onlinelibrary.wiley.com →
Cited in this study
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review
No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.
research Cicatricial (Scarring) Alopecias
Scarring alopecias are complex hair loss disorders that require early treatment to prevent permanent hair loss.
Related
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.